No profile data available.
Entrada Therapeutics, Inc. (TRDA) is a healthcare company in the brain and nerve treatment drugs industry, based in Boston, United States, with about 152 full-time employees.
It reported revenue of $25.42 million for fiscal year 2025, down 87.9% from fiscal year 2024, and net income of -$143.75 million. Its market capitalization was $220.77 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible.
Entrada Therapeutics reported $25.42 million in revenue for fiscal year 2025, down 87.9% from $210.78 million in fiscal year 2024.
$220.77 million as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Inhibikase Therapeutics, Inc. (IKT), AC Immune SA (ACIU), Alector, Inc. (ALEC), Alpha Cognition Inc. (ACOG).